Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JV-213 is an investigational autologous chimeric antigen receptor (CAR) T cell therapy that targets CD79b, a component of the B-cell antigen receptor complex. It is designed to treat adults with relapsed or refractory B-cell lymphomas by engineering a patient's own T cells to express a CAR specific for CD79b. Upon administration, these modified T cells selectively bind to and induce cytotoxicity in CD79b-expressing tumor cells. The therapy is currently being evaluated in phase 1 clinical trials for safety, tolerability, and preliminary efficacy. This is the first-in-human study of this product and it has not yet been approved or commercially released[1][2][3][4][5][6][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JV-213.